- Home
- GRCE vs EQ Comparison
GRCE vs EQ Comparison
Compare GRCE & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRCE
- EQ
- Stock Information
- Founded
- GRCE 2002
- EQ 2017
- Country
- GRCE United States
- EQ United States
- Employees
- GRCE N/A
- EQ N/A
- Industry
- GRCE
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- GRCE
- EQ Health Care
- Exchange
- GRCE NYSE
- EQ Nasdaq
- Market Cap
- GRCE 30.9M
- EQ 24.8M
- IPO Year
- GRCE N/A
- EQ 2018
- Fundamental
- Price
- GRCE $3.34
- EQ $0.77
- Analyst Decision
- GRCE
- EQ Buy
- Analyst Count
- GRCE 0
- EQ 2
- Target Price
- GRCE N/A
- EQ $5.00
- AVG Volume (30 Days)
- GRCE 29.7K
- EQ 247.2K
- Earning Date
- GRCE 11-13-2024
- EQ 11-13-2024
- Dividend Yield
- GRCE N/A
- EQ N/A
- EPS Growth
- GRCE N/A
- EQ N/A
- EPS
- GRCE N/A
- EQ N/A
- Revenue
- GRCE N/A
- EQ $45,914,000.00
- Revenue This Year
- GRCE N/A
- EQ $4.76
- Revenue Next Year
- GRCE N/A
- EQ N/A
- P/E Ratio
- GRCE N/A
- EQ N/A
- Revenue Growth
- GRCE N/A
- EQ 7.70
- 52 Week Low
- GRCE $1.98
- EQ $0.48
- 52 Week High
- GRCE $3.60
- EQ $3.25
- Technical
- Relative Strength Index (RSI)
- GRCE N/A
- EQ 45.78
- Support Level
- GRCE N/A
- EQ $0.68
- Resistance Level
- GRCE N/A
- EQ $0.79
- Average True Range (ATR)
- GRCE 0.00
- EQ 0.07
- MACD
- GRCE 0.00
- EQ 0.01
- Stochastic Oscillator
- GRCE 0.00
- EQ 47.83
About GRCE GRACE THERAPEUTICS INC
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.